Healthleap Raises $38 Million to Flag Hospital Patients Who May Need Closer Review

Highlights

Healthleap has raised $38 million to develop its AI-powered platform for identifying hospitalized patients who may have overlooked or undiagnosed conditions. The funding comprises an $8 million seed round and a $30 million Series A. The company connects to electronic health record systems and analyzes clinical notes alongside structured data, then sends risk information to care teams for additional review—not diagnosis. Its platform is deployed in more than 50 hospitals and screens for conditions including malnutrition and delirium. Healthleap says its malnutrition program at the Hospital of the University of Pennsylvania generated $23.8 million in annualized financial impact. The company plans to expand its engineering, product, sales, and customer success teams while adding support for more conditions.

Sentiment Analysis

• Overall tone: The article is primarily neutral and business-focused, reporting a funding announcement, product capabilities, customers, and expansion plans.
• Positive signals: Healthleap has grown from three hospital partners to more than 50 over the past year, and the company reports that revenue grew more than 10x during that period. It also cites customer-reported financial returns and a substantial impact at the Hospital of the University of Pennsylvania.
• Measured framing: The article distinguishes between identifying risk and diagnosing disease. Healthleap’s software flags patients for further review, and several condition-identification programs are still undergoing further clinical validation.
• Limitations and uncertainty: The company does not disclose its valuation or specific revenue figures. The financial and clinical performance figures are attributed to Healthleap, while the article does not independently establish their broader applicability.
• Assessment: The coverage presents a cautiously positive outlook on the company’s growth and potential, balanced by clear caveats about validation, disclosed evidence, and the software’s role.

Article Text

Healthleap, a startup developing an artificial intelligence platform for identifying hospital patients who may have undiagnosed health conditions, has raised $38 million in seed and Series A funding. TechCrunch reported the financing exclusively. The company has not disclosed its valuation. The funding consists of an $8 million seed round co-led by Sequoia Capital and First Round Capital, followed by a $30 million Series A led by Hummingbird Ventures.

The company was founded in South Africa in 2022 by siblings Jemima and Josiah Meyer. Its first product was a clinical nutrition tool that Jemima developed for dietitians. Healthleap later changed direction, building a broader platform intended to help hospitals identify patients who may have conditions that are not recognized early, including malnutrition and delirium. Josiah Meyer, the company’s CEO and co-founder, described the shift to TechCrunch.

The platform is designed to examine information in electronic health records. Patient records contain structured details, such as laboratory results, weights, and vital signs, as well as narrative notes written by clinicians. Those notes may describe symptoms and changes that are not captured as neatly in structured fields, including poor appetite, recent weight loss, muscle loss, or difficulty swallowing. Healthleap uses language models to find affirmative or negated mentions of clinical concepts in these records and combines the extracted information with structured data in risk models.

Healthleap says the software identifies people who may warrant closer attention; it does not diagnose patients. Each night, the platform analyzes adult inpatient records, including lab results, vital signs, weights, medications, diet orders, diagnoses, and clinicians’ notes. The company says it then writes risk scores into the care team’s existing workflow each morning. A dashboard provides additional information about patients’ trends, giving clinicians material to consider during further review.

The platform is deployed in more than 50 hospitals and currently screens for conditions including malnutrition and delirium. Healthleap has also developed programs to identify aspiration pneumonia, pressure ulcers, and risk of readmission for congestive heart failure. Josiah Meyer said those programs are undergoing further clinical validation. Malnutrition was an initial focus in part because it can go undiagnosed and may affect recovery. Research cited in the article suggests that 20% to 50% of hospital inpatients are malnourished. Some studies have associated malnutrition with longer hospital stays, impaired wound healing, infections, other complications, and higher morbidity and mortality.

According to Meyer, Healthleap expanded from three hospital partners to more than 50 over the past year. Its customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. He also said revenue grew more than 10x over the same period, but did not provide specific revenue figures. These customer and growth metrics are presented as statements from the company rather than as independently detailed financial disclosures.

Healthleap sells three-year contracts priced according to each hospital’s licensed bed count and also uses outcome-based pricing. Meyer said the company bases its measurable return on investment on results validated and attributed by a hospital’s finance team. He stated that contracts are structured to deliver multiples of their price and that every customer has seen a 5x hard ROI or more, with some reaching over 20x annual total ROI. These results are claims reported by the company.

At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program produced $23.8 million in annualized financial impact. The company attributed $6.3 million to additional reimbursement and $17.5 million to shorter hospital stays. These figures illustrate the financial outcomes Healthleap says its hospital program can generate, while the software itself remains a tool for identifying risk and supporting clinical review.

The new funding is intended to support hiring and investment in engineering, product, sales, and customer success as Healthleap adds coverage for more conditions. Meyer said the company’s longer-term aim is to address more than 40 major health conditions and expand beyond inpatient hospitals into outpatient and home care. The company’s plans therefore combine broader clinical coverage with expansion into additional care settings, while some of its developing programs continue through clinical validation.

Key Insights Table